Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.83 |
| ▸ | CA1 | P00915 | 4/20 | 0.83 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.52 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.52 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.48 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.48 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | LCK | P06239 | 1/20 | 0.45 |
| ▸ | PPARD | Q03181 | 1/20 | 0.45 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.45 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4616998 | 1.00 | CA2 (0.83) | CA2CA1MAPK1GRIK1GRIK2 | |
| SCHEMBL28237938 | 1.00 | CA2 (0.83) | CA2CA1MAPK1GRIK1GRIK2 | |
| SCHEMBL1665997 | 1.00 | CA2 (0.83) | CA2CA1MAPK1GRIK1GRIK2 | |
| SCHEMBL28156543 | 1.00 | CA2 (0.83) | CA2CA1MAPK1GRIK1GRIK2 | |
| SCHEMBL3628614 | 1.00 | CA2 (0.83) | CA2CA1MAPK1GRIK1GRIK2 | |
| SCHEMBL5090059 | 1.00 | CA2 (0.83) | CA2CA1MAPK1GRIK1GRIK2 | |
| SCHEMBL3859929 | 1.00 | CA2 (0.83) | CA2CA1MAPK1GRIK1GRIK2 | |
| SCHEMBL6119566 | 1.00 | CA2 (0.83) | CA2CA1MAPK1GRIK1GRIK2 | |
| SCHEMBL10706703 | 1.00 | CA2 (0.83) | CA2CA1MAPK1GRIK1GRIK2 | |
| Hydrochloric Acid SCHEMBL22235759 | 0.98 | CA2 (0.80) | CA2CA1MAPK1GRIK1GRIK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118201915-A | Pyridazinylamino derivatives as ALK5 inhibitors | 奇斯药制品公司 | 2024-06-14 | — | — | CN | claimed |
| CN-115151534-B | Inhibitors of interleukin-1 receptor associated kinase (IRAK)/FMS-like receptor tyrosine kinase (FLT 3), pharmaceutical products thereof and methods of use thereof | 南京药石科技股份有限公司 | 2024-02-06 | — | — | CN | claimed |
| EP-4073057-B1 | NEW FYN AND VEGFR2 KINASE INHIBITORS | Rottapharm Biotech Srl (IT) | 2023-11-29 | — | — | EP | claimed |
| CN-116648451-A | Antagonist compounds | 阿道尔克斯治疗有限公司 | 2023-08-25 | — | — | CN | claimed |
| CN-116096719-A | Pyridazinylamino derivatives as ALK5 inhibitors | 奇斯药制品公司 | 2023-05-09 | — | — | CN | claimed |
| US-20230061118-A1 | NEW FYN AND VEGFR2 KINASE INHIBITORS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2023-03-02 | — | — | US | claimed |
| CN-115279747-A | Novel fYN and VEGFR2 kinase inhibitors | 罗达制药生物技术有限责任公司 | 2022-11-01 | — | — | CN | claimed |
| CN-115151534-A | Inhibitors of interleukin-1 receptor-related kinase (IRAK)/FMS-like receptor tyrosine kinase (FLT 3), pharmaceutical products thereof, and methods thereof | 南京药石科技股份有限公司 | 2022-10-04 | — | — | CN | claimed |
| CN-109661396-B | Spiro-fused cyclic ureas as ROCK inhibitors | 百时美施贵宝公司 | 2022-07-01 | — | — | CN | claimed |
| WO-2021159993-A1 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR ASSOCIATED KINASE (IRAK) /FMS-LIKE RECEPTOR TYROSINE KINASE (FLT3), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF | PHARMABLOCK SCIENCES (NANJING) , INC. (CN) | 2021-08-19 | — | — | WO | claimed |
| WO-2021116005-A1 | NEW FYN AND VEGFR2 KINASE INHIBITORS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2021-06-17 | — | — | WO | claimed |
| WO-2021115560-A1 | NEW FYN AND VEGFR2 KINASE INHIBITORS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2021-06-17 | — | — | WO | claimed |
| CN-106660954-A | Substituted azaspiro(4.5)decane derivatives | 格吕伦塔尔有限公司 | 2017-05-10 | — | — | CN | claimed |
| CN-103179966-A | Vitamin E formulations of sulfonamide NS3 inhibitors | NOVARTIS AG | 2013-06-26 | — | — | CN | claimed |
| EP-2485678-A1 | COFERONS AND METHODS OF MAKING AND USING THEM | Cornell University (US) | 2012-08-15 | — | — | EP | claimed |
| CN-102365276-A | Substituted spiro-amide compounds | GRUENENTHAL GMBH | 2012-02-29 | — | — | CN | claimed |
| WO-2011043817-A1 | COFERONS AND METHODS OF MAKING AND USING THEM | CORNELL UNIVERSITY (US) | 2011-04-14 | — | — | WO | claimed |
| EP-1124811-A1 | 2-UREIDO-THIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA & UPJOHN S.p.A. (IT) | 2001-08-22 | — | — | EP | claimed |
| WO-2000026203-A1 | 2-UREIDO-THIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA & UPJOHN S.P.A. (IT) | 2000-05-11 | — | — | WO | claimed |
| US-5846990-A | Substituted biphenyl isoxazole sulfonamides | BRISTOL-MYERS SQUIBB CO. (US) | 1998-12-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230061118-A1 | NEW FYN AND VEGFR2 KINASE INHIBITORS | FYN, SRC, PTK2B | CA2 1937/4885CA1 4227/4885MAPK1 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.